Showing 1 to 12 of 12 results
Weight-Loss Drugs Halve Heart Failure Hospitalizations and Deaths
A large-scale study reveals that GLP-1 agonists, semaglutide and tirzepatide, significantly reduce hospitalizations and mortality risk by 42% and 58%, respectively, in obese heart failure patients with type 2 diabetes.
Weight-Loss Drugs Halve Heart Failure Hospitalizations and Deaths
A large-scale study reveals that GLP-1 agonists, semaglutide and tirzepatide, significantly reduce hospitalizations and mortality risk by 42% and 58%, respectively, in obese heart failure patients with type 2 diabetes.
Progress
32% Bias Score
Tirzepatide Shows Superior Weight Loss Compared to Semaglutide in Clinical Trial
A new study comparing tirzepatide and semaglutide in 751 obese participants found tirzepatide produced significantly greater weight loss (average 50 pounds, 20.2% body weight) versus semaglutide (average 33 pounds, 13.7%), attributed to its dual hormone action; however, the study's open-label design...
Tirzepatide Shows Superior Weight Loss Compared to Semaglutide in Clinical Trial
A new study comparing tirzepatide and semaglutide in 751 obese participants found tirzepatide produced significantly greater weight loss (average 50 pounds, 20.2% body weight) versus semaglutide (average 33 pounds, 13.7%), attributed to its dual hormone action; however, the study's open-label design...
Progress
52% Bias Score
New Obesity Drugs Achieve Significant Weight Loss, Challenging Traditional Approaches
New drugs, such as semaglutide and tirzepatide, are revolutionizing obesity treatment by mimicking key hormones that regulate appetite and metabolism, achieving significant weight loss (up to 25%) in clinical trials, while traditional methods often fail in the long term; this has led to a surge in p...
New Obesity Drugs Achieve Significant Weight Loss, Challenging Traditional Approaches
New drugs, such as semaglutide and tirzepatide, are revolutionizing obesity treatment by mimicking key hormones that regulate appetite and metabolism, achieving significant weight loss (up to 25%) in clinical trials, while traditional methods often fail in the long term; this has led to a surge in p...
Progress
48% Bias Score
Lilly Intervenes in Lawsuit over Compounded Tirzepatide Drugs
Eli Lilly joined a lawsuit against the FDA, contesting the agency's October 2023 decision ending the shortage designation for its tirzepatide-based drugs (Zepbound and Mounjaro), impacting the legality of cheaper compounded alternatives. The FDA affirmed its decision in December, but the compounding...
Lilly Intervenes in Lawsuit over Compounded Tirzepatide Drugs
Eli Lilly joined a lawsuit against the FDA, contesting the agency's October 2023 decision ending the shortage designation for its tirzepatide-based drugs (Zepbound and Mounjaro), impacting the legality of cheaper compounded alternatives. The FDA affirmed its decision in December, but the compounding...
Progress
36% Bias Score
FDA Approves Zepbound for Obstructive Sleep Apnea Treatment
The FDA approved Eli Lilly's Zepbound (tirzepatide) as the first medication to treat obstructive sleep apnea in obese adults, following two successful 52-week studies demonstrating significant symptom reduction.
FDA Approves Zepbound for Obstructive Sleep Apnea Treatment
The FDA approved Eli Lilly's Zepbound (tirzepatide) as the first medication to treat obstructive sleep apnea in obese adults, following two successful 52-week studies demonstrating significant symptom reduction.
Progress
32% Bias Score
Zepbound Shows 47% Greater Weight Loss Than Wegovy in Obesity Trial
A clinical trial showed that adults using the obesity drug Zepbound lost 47% more weight on average than those using Wegovy after 18 months, achieving an average weight loss of 50 pounds compared to 33 pounds, respectively.
Zepbound Shows 47% Greater Weight Loss Than Wegovy in Obesity Trial
A clinical trial showed that adults using the obesity drug Zepbound lost 47% more weight on average than those using Wegovy after 18 months, achieving an average weight loss of 50 pounds compared to 33 pounds, respectively.
Progress
48% Bias Score
Counterfeit Weight-Loss Drugs: A Global Health Crisis
The high demand for weight-loss drugs like Ozempic has created shortages, leading to a surge in counterfeit medications globally, with the World Health Organization estimating 10% of medicines are fake; this is fueled by compounding pharmacies and exacerbated by inadequate consumer awareness.
Counterfeit Weight-Loss Drugs: A Global Health Crisis
The high demand for weight-loss drugs like Ozempic has created shortages, leading to a surge in counterfeit medications globally, with the World Health Organization estimating 10% of medicines are fake; this is fueled by compounding pharmacies and exacerbated by inadequate consumer awareness.
Progress
44% Bias Score
Weight Regain After Stopping Weight-Loss Injections: An Oxford Study
A University of Oxford study reveals that individuals using weight-loss injections regain a significant portion of lost weight within 10 months of stopping treatment, regardless of the injection type; newer, more effective drugs lead to greater weight loss but also greater weight regain.
Weight Regain After Stopping Weight-Loss Injections: An Oxford Study
A University of Oxford study reveals that individuals using weight-loss injections regain a significant portion of lost weight within 10 months of stopping treatment, regardless of the injection type; newer, more effective drugs lead to greater weight loss but also greater weight regain.
Progress
48% Bias Score
GLP-1 Agonist Shows Significant Promise in Treating Obstructive Sleep Apnea
A year-long study published in The New England Journal of Medicine showed that tirzepatide, a GLP-1 agonist, reduced the apnea-hypopnea index by almost 59% in 469 obese individuals with moderate-to-severe obstructive sleep apnea, alongside an average 20% weight loss; this may reduce reliance on CPAP...
GLP-1 Agonist Shows Significant Promise in Treating Obstructive Sleep Apnea
A year-long study published in The New England Journal of Medicine showed that tirzepatide, a GLP-1 agonist, reduced the apnea-hypopnea index by almost 59% in 469 obese individuals with moderate-to-severe obstructive sleep apnea, alongside an average 20% weight loss; this may reduce reliance on CPAP...
Progress
48% Bias Score
FDA Approves First Prescription Drug for Obstructive Sleep Apnea
The FDA approved Zepbound, a GLP-1 receptor agonist, as the first prescription drug for moderate-to-severe obstructive sleep apnea in obese patients; clinical trials showed significant improvements in breathing disruptions and weight loss (18-20%), potentially impacting the 30 million Americans with...
FDA Approves First Prescription Drug for Obstructive Sleep Apnea
The FDA approved Zepbound, a GLP-1 receptor agonist, as the first prescription drug for moderate-to-severe obstructive sleep apnea in obese patients; clinical trials showed significant improvements in breathing disruptions and weight loss (18-20%), potentially impacting the 30 million Americans with...
Progress
44% Bias Score
Zepbound Outperforms Wegovy in 72-Week Weight Loss Trial
A new, yet un-peer-reviewed study shows Eli Lilly's Zepbound (tirzepatide) enabled 20% weight loss in 72 weeks among 751 obese or overweight participants, exceeding Wegovy's (semaglutide) under 14% weight loss; this translates to approximately 50 pounds lost with Zepbound versus 33 pounds with Wegov...
Zepbound Outperforms Wegovy in 72-Week Weight Loss Trial
A new, yet un-peer-reviewed study shows Eli Lilly's Zepbound (tirzepatide) enabled 20% weight loss in 72 weeks among 751 obese or overweight participants, exceeding Wegovy's (semaglutide) under 14% weight loss; this translates to approximately 50 pounds lost with Zepbound versus 33 pounds with Wegov...
Progress
40% Bias Score
Weight-Loss Injections Strain UK NHS
Two injectable weight-loss medications, Wegovy and Mounjaro, are showing efficacy in the UK, but concerns exist regarding increased demand on the NHS, limited availability, and private market costs ranging from £200-£300 per pen.
Weight-Loss Injections Strain UK NHS
Two injectable weight-loss medications, Wegovy and Mounjaro, are showing efficacy in the UK, but concerns exist regarding increased demand on the NHS, limited availability, and private market costs ranging from £200-£300 per pen.
Progress
20% Bias Score
Showing 1 to 12 of 12 results